“Peace I leave with you; my peace I give you. I do not give to you as the world gives. Do not let your hearts be troubled and do not be afraid.” – John 14:27 The post Peace I leave with you; my peace I give you … appeared first on Let Life Happen ..read more

By: Diane Mapes From: fredhutch.org Fred Hutch’s health services researcher Joe Unger, PhD, MS, working with the American Society of Clinical Oncology (ASCO), the U.S. Food & Drug Administration (FDA) and the Friends of Cancer Research, published a study last week that found clinical trials have started to modify eligibility criteria to be more inclusive of patients with brain metastasis, per the collaboration’s 2017 task force recommendation. Unger and others evaluated more than 3,000 interventional clinical trials for metastatic breast, colorectal, lung and skin cancers (melanoma) held b ..read more

By: University of Texas M. D. Anderson Cancer Center From: medicalxpress.com Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays and improved patient satisfaction. The Phase II trial results, published in JAMA Network Open, evaluated 49 patients who received radiation therapy followed by mastectomy with immediate breast reconstruction. There were no co ..read more

For anyone facing a mastectomy, one of the main issues to be decided is whether to undergo reconstruction. In my case, it was never a matter of whether or not I would have reconstruction; it was a given based upon the recommendation of the cancer surgeon. I was very grateful that the decision was made immediately at the time of our discussing my second cancer surgery. This afforded me the opportunity to meet with the cosmetic surgeon who would be present at the cancer surgery and would be placing the expanders during the same surgery thus eliminating a separate surgery later on. The next cours ..read more

“Do not let the roles you play in life make you forget who you are.” – Roy T. Bennett The post Do not let the roles you play … appeared first on Let Life Happen ..read more

By: Erin Dahlstrom, Ph.D From: mdanderson.org PARP inhibitors are a type of targeted therapy commonly used to treat breast cancer and ovarian cancer, among others. They target PARP, or poly (ADP-ribose) polymerase, which is a protein in cells that helps repair damaged DNA. DNA damage is a normal part of a cell’s life cycle, and it doesn’t prevent cells from growing and dividing, as long as they can repair the damage. “PARP inhibitors are a class of drug that interferes with a cell’s ability to repair its DNA,” says Jennifer Litton, M.D., vice president of Clinical Research. How PARP inhibitors ..read more

“You were born to stand out, stop trying to fit in.” – Roy T. Bennett, The Light in the Hear The post You were born to stand out … appeared first on Let Life Happen ..read more

By: University of Colorado Cancer Center From: cancerhealth.com University of Colorado cancer researchers explore ways to overcome resistance to a standard treatment for triple-negative breast cancer Research led by University of Colorado Cancer Center members points to a combination of drugs as a potential treatment option for a type of aggressive breast cancer. Todd Pitts, PhD, and Jennifer Diamond, MD, co-authored a paper, published on March 1 in the journal Breast Cancer Research, on their study of ways to overcome resistance to doxorubicin, a type of chemotherapy drug that slows or stops ..read more

“Gratitude builds a bridge to abundance.” – Roy T. Bennett, The Light in the Heart The post Gratitude builds a … appeared first on Let Life Happen ..read more

By: Ashling Wahner From: onclive.com The FDA has granted orphan drug designation to utidelone injectable (UTD1) as a potential therapeutic option for patients with breast cancer brain metastases, according to an announcement from Biostar Pharma.1 Unlike most macromolecular drugs, utidelone can cross the blood-brain barrier because of its unique physiochemical characteristics and its insusceptibility to P-glycoprotein–mediated efflux. The orphan drug designation was based on data from 2 phase 2 trials. In the phase 2 UTOBIA-BM trial (NCT05781633) of UTD1 plus etoposide and bevacizumab (Avastin ..read more